These findings suggest that the mechanisms of restrictive immunodominance observed in murine schistosomiasis may be applicable to human CD4+ T cell-mediated diseases, offering potential therapeutic avenues for preventing or mitigating disease severity by targeting and neutralizing restrictive immunodominance. Here, CD4 is linked to schistosomiasis.